MAS-825

Summary

Mas-825 (CHEMBL5315029) is a phase-3 clinical-stage unknown; indicated across 3 conditions including lymphoproliferative syndrome and hidradenitis suppurativa.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315029
Name	MAS-825
Type	Unknown
Max phase	3

Also known as: Mas 825, Mas-825, Mas825, MAS-825

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lymphoproliferative syndrome	3	MONDO:0016537	MONDO:0010627
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06309823	PHASE3	COMPLETED	A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency
NCT03827798	PHASE2	ACTIVE_NOT_RECRUITING	Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT04641442	PHASE2	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
NCT07203001	PHASE2	RECRUITING	A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still’s Disease
NCT04382651	PHASE2	COMPLETED	Study of Efficacy and Safety of MAS825 in Patients With COVID-19
NCT06097663	PHASE2	COMPLETED	A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT04665154	PHASE1	COMPLETED	A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).